HPMC & sodium hyaluronate cause IOP increases

Article

Sodium hyaluronate 1% and hydroxypropylmethylcellulose 2% (HPMC) can cause significant intraocular pressure (IOP) increases during the first eight hours following cataract surgery.

Sodium hyaluronate 1% and hydroxypropylmethylcellulose 2% (HPMC) can cause significant intraocular pressure (IOP) increases during the first eight hours following cataract surgery, according to a study published in the June issue of Ophthalmology.

Georg Rainer and colleagues from the Medical University of Vienna, Austria enrolled 80 eyes of 40 patients with bilateral age-related cataract. The subjects were randomized to receive either sodium hyaluronate 1% or HPMC 2% during cataract surgery of the first eye. The second eye received an alternative viscosurgical device. IOP was measured preoperatively and 30 minutes, one, two, three, four, six, eight, 20 and 24 hours and one week postoperatively.

The researchers found that the highest mean IOP increase occurred at eight hours postoperatively (5.3±6.4 mmHg) in the sodium hyaluronate 1% group and at two hours postoperatively in the HPMC 2% group (7.8±6.1 mmHg). The mean IOP increase was higher in the HPMC 2%group (r=0.005). IOP spikes (≥30 mmHg) were seen in five eyes (13%) of the sodium hyaluronate 1% group and 13 eyes (33%) of the HPMC 2% group.

It was concluded from the study results that both sodium hyaluronate 1%% and HPMC 2% can cause significant IOP increases during the first eight hours following surgery.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.